Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Acq. announced
Quarterly results
Appointed director
CC transcript
PLUS THERAPEUTICS, INC. (CYTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Investor Contact"
05/16/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements AUSTIN, Texas, May 16, 2023 - Plus Therapeutics, Inc. , a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that it has received notification from The Nasdaq Stock Market LLC that the staff has determined that for the last 10 consecutive business days, from May 1, 2023 to May 12, 2023, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Therefore, the Company has regained compliance with Listing Rule 5550. Accordingly, Nasdaq has advised that the matter is now closed. About Plus Therapeutics Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing t..."
04/28/2023 8-K Quarterly results
04/21/2023 8-K Quarterly results
04/20/2023 8-K Quarterly results
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
02/23/2023 8-K Quarterly results
Docs: "Peter Vozzo ICR Westwicke 377-4767 [email protected] Terri Clevenger ICR Westwicke 856-4326 [email protected]"
12/15/2022 8-K Quarterly results
11/28/2022 8-K Quarterly results
10/20/2022 8-K Quarterly results
09/22/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "OWNERSHIP AND INTELLECTUAL PROPERTY PROTECTION",
"Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas"
09/09/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Distribution Agreement, by and among Plus Therapeutics, Inc. and Canaccord Genuity LLC",
"Opinion of Hogan Lovells LLP"
08/17/2022 8-K Other Events  Interactive Data
Docs: "FORM 8-K"
08/08/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Purchase Agreement, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC",
"Registration Rights Agreement, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC"
07/21/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
04/21/2022 8-K Quarterly results
Docs: "Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights First patient dosed in ReSPECT-LM Phase 1/2a dose escalation trial of 186 RNL for leptomeningeal metastases"
04/05/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership Companies collaborate to design innovative registrational trial of 186 RNL for recurrent glioblastoma"
02/24/2022 8-K Quarterly results
01/14/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Distribution Agreement, by and among Plus Therapeutics, Inc. and Canaccord Genuity LLC",
"Opinion of Hogan Lovells LLP"
01/06/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Plus Therapeutics Significantly Expands Investigational Oncology Drug Pipeline"
11/18/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Plus Therapeutics Announces Positive Interim Data from ReSPECT ™ -GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting"
10/21/2021 8-K Quarterly results
Docs: "Plus Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights Management to host conference call today at 5:00 p.m. ET"
09/21/2021 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amended and Restated Bylaws of Plus Therapeutics, Inc",
"Certificate of Elimination of Series A Preferred Stock"
09/13/2021 8-K Quarterly results
07/22/2021 8-K Quarterly results
Docs: "Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights Management to host conference call today at 5:00 pm ET"
05/20/2021 8-K Quarterly results
04/22/2021 8-K Quarterly results
02/23/2021 8-K Quarterly results
02/22/2021 8-K Quarterly results
01/12/2021 8-K Quarterly results
10/23/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : October 23, 2020 PLUS THERAPEUTICS, INC. Delaware 001-34375 33-0827593 4200 Marathon Blvd., Suite 200, Austin, Texas 78756 255-7194 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under...",
"Distribution Agreement, by and among Plus Therapeutics, Inc. and Canaccord Genuity LLC",
"Opinion of Pillsbury Winthrop Shaw Pittman LLP"
10/22/2020 8-K Quarterly results
Docs: "Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights – Received FDA Orphan Drug and Fast Track designations for novel glioblastoma radiotherapy –"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy